Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

nical trial data) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contact

David A. Ramsay Karen Sparks / Joleen Schultz

Chief Financial Officer Mentus

(858) 704-8260 (858) 455-5500, x275/x215

dramsay@halozyme.com karen@mentus.com

jschultz@mentus.com

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007

Three Months Ended

March 31,

2008 2007

REVENUES:

Product sales $141,438 $187,086

Revenue under collaborative agreements 1,664,080 623,129

Total Revenues 1,805,518 810,215

OPERATING EXPENSES:

Cost of product
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... LabStyle Innovations Corp. (OTCQB: DRIO), developer ... it recently closed a round of funding totaling ... support the global rollout and initial U.S. commercial ... management solution that includes novel software applications combined ... device, and for working capital purposes. The Dario ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... There’s a ... Minerva is the first commercially available new FDA approved system in the last ... rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... , , , , , The programming example given below shows a , ... , , , , , ... Explanation, , , ... Temperature control for the , block., ...
... , , , , , ... Variable heating and cooling rates, which can be programmed as desired with , ... aligned to the temperature. , , ... it may be necessary to heat , up carefully after annealing. , ...
... , , , , , , ... only) , , ... gradient may be programmed , with ... The most common application is the determination of the optimal annealing , ...
Cached Biology Technology:Title 2
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... orthopaedists and a wide number of specialists concerned with ... Asia-Pacific,s key clinical bone event in 2013. The ... cooperation with the Hong Kong Osteoporosis Foundation and the ... December 12-15, 2013 in Hong Kong. More than ...
... (February 26th, 2013) Canadian agriculture is faced ... risks and uncertainties. An expert panel convened by ... water and land resources in Canada can be ... effective land and water management strategies, adopting effective ...
Cached Biology News:Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Report: 'Water and Agriculture in Canada: Towards Sustainable Management of Water Resources' 2
ready-to-use solution...
... MS/MS analysis & visualization ... across multiple samples. Combine ... for increased confidence. Get ... information from your MS/MS ...
... Synthetic peptide derived from the N-terminal ... dog and orangutang occludin proteins. ... protein. Reactivity: Human (positive controls: ... rat mouse dog and orangutang is ...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: